Group 1 - Approval Status: HLX43 (a PD-L1 targeted antibody-drug conjugate) in combination with HLX07 (an anti-EGFR monoclonal antibody) and Hansizhuang (Sruvelizumab) has received approval from NMPA for clinical trials aimed at treating advanced solid tumors in China [1] Group 2 - R&D Progress: Phase 1/2 clinical trials for HLX43 are being conducted in multiple regions including China, the United States, and Japan, covering indications such as NSCLC, colorectal cancer, cervical cancer, and esophageal squamous cell carcinoma [2] - Clinical Data: In patients with previously treated NSCLC, the overall response rate (ORR) reached 37.0% and the disease control rate (DCR) was 87.0%; for cervical cancer patients, the ORR was 41.4% (with the 3.0 mg/kg dosage group achieving 70%) [2] - Market Position: There are currently no similar combination therapies approved for marketing globally [2]
复宏汉霖：HLX43三联疗法获NMPA批准开展临床试验